Humacyte (NASDAQ:HUMA – Get Free Report) announced its earnings results on Friday. The company reported ($0.13) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.13), FiscalAI reports. The business had revenue of $0.47 million for the quarter, compared to analysts’ expectations of $1.35 million.
Here are the key takeaways from Humacyte’s conference call:
- Commercial launch momentum for Symvess — 27 VAC approvals to date, 43 VAC reviews pending, 27 hospitals have ordered (most reordering), and the price cut to $17,000 has raised VAC success to ~70% and increased repeat usage.
- First-of-its-kind U.S. Department of Defense funding has been allocated for procurement and training of biologic vascular repair technologies, which could drive meaningful adoption and non‑commercial volume in 2026.
- Dialysis access is a near-term regulatory catalyst: positive V007 two‑year results support ATEV, the V012 interim analysis (first 80 patients to one year) will report by early June 2026, and Humacyte plans a supplemental BLA submission in H2 2026 if results are supportive.
- Financial mix is mixed — Q4 net loss widened to $24.8M largely due to an $8.9M inventory reserve and unused capacity costs, but FY25 net loss improved to $40.8M year-over-year and liquidity was bolstered by ~$50M cash at year‑end plus subsequent equity raises and a $40M initial tranche of a $77.5M credit facility.
- Pipeline progress beyond trauma — the CTEV coronary graft completed positive preclinical work, an IND was submitted and commercial-scale manufacturing started, targeting first‑in‑human coronary trials in H2 2026.
Humacyte Trading Down 13.2%
Shares of NASDAQ:HUMA opened at $0.68 on Friday. The company has a market capitalization of $126.52 million, a PE ratio of -3.38 and a beta of 1.89. The company has a current ratio of 1.62, a quick ratio of 0.90 and a debt-to-equity ratio of 2.97. Humacyte has a 12-month low of $0.67 and a 12-month high of $2.93. The business’s fifty day simple moving average is $1.04 and its 200-day simple moving average is $1.28.
Analyst Upgrades and Downgrades
Key Stories Impacting Humacyte
Here are the key news stories impacting Humacyte this week:
- Positive Sentiment: D. Boral Capital reaffirmed a “buy” rating and set an outsized $25.00 price target, signaling strong upside expectations from that firm. Benzinga
- Positive Sentiment: Humacyte named Rick McElheny SVP of Business Development to expand collaborations and commercialization efforts—management hire aimed at accelerating partnerships that could drive future revenue. GlobeNewswire: Appointment
- Neutral Sentiment: Full earnings call transcript is available for investors wanting management commentary and Q&A that could clarify outlook and commercial plans. Earnings Call Transcript
- Negative Sentiment: Q4 results: GAAP loss of ($0.13) per share met consensus, but revenue came in at roughly $0.47–0.5M versus analyst expectations near $1.35M (and full‑year sales only $2.0M). The revenue shortfall and low near-term sales reduce near-term visibility and likely pressured the stock. MarketBeat: Earnings Press Release Zacks
- Negative Sentiment: BTIG reduced its price target from $6.00 to $3.00 (still a “buy”), signaling a more cautious near-term outlook from another sell-side firm and lowering consensus upside. Benzinga
Institutional Investors Weigh In On Humacyte
A number of institutional investors have recently added to or reduced their stakes in HUMA. Geode Capital Management LLC grew its stake in Humacyte by 33.4% in the second quarter. Geode Capital Management LLC now owns 2,948,508 shares of the company’s stock valued at $6,163,000 after purchasing an additional 738,142 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Humacyte by 31.3% during the second quarter. JPMorgan Chase & Co. now owns 70,067 shares of the company’s stock valued at $146,000 after buying an additional 16,702 shares during the last quarter. Rhumbline Advisers boosted its holdings in shares of Humacyte by 51.1% in the 2nd quarter. Rhumbline Advisers now owns 177,623 shares of the company’s stock valued at $371,000 after buying an additional 60,059 shares in the last quarter. Prudential Financial Inc. bought a new stake in shares of Humacyte in the 2nd quarter valued at about $28,000. Finally, Marshall Wace LLP grew its position in shares of Humacyte by 5,308.2% in the 2nd quarter. Marshall Wace LLP now owns 2,639,194 shares of the company’s stock worth $5,516,000 after buying an additional 2,590,394 shares during the last quarter. Institutional investors own 44.71% of the company’s stock.
Humacyte Company Profile
Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.
The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.
Recommended Stories
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
